Alber & Geiger is a political lobbying powerhouse.

We represent our clients’ interests on the highest EU levels. Our firm combines former top EU officials, leading EU politicians and high profile EU attorneys.

We combine legal expertise with lobbying knowledge. This is what sets us apart.

Work

Alber & Geiger is known for getting things done. For us, only results count. This is why time and again we deliver the integrated strategies organizations need to be successful. And we have the record to prove it.

Government Affairs

Government Affairs

Alber & Geiger is a political lobbying powerhouse and a leading European government relations law firm. We represent our clients’ interests on the highest diplomatic and political level.
Read More

Diplomacy

Diplomacy

Alber & Geiger helps countries and companies with advocacy on bilateral political and economic relations, especially to implement strategic plans and raise visibility to and before the EU institutions in Brussels.
Read More

Litigation

Litigation

Our reputation as trial lawyers before the Court of Justice of the European Union (CJEU), the European Court of Human Rights (ECHR), and the Administrative Tribunal of the International Labour Organisation (ILO) is well known.
Read More

Wins

Alber & Geiger is known for getting things done. For us, only results count. This is why time and again we deliver the integrated strategies organizations need to be successful. And we have the record to prove it.

Challenge

Alber & Geiger assisted West Pharmaceutical, a US corporation and world market leader in medical devices, paving the way for PFAS ban exemptions for their products. The intention was to prevent disruptions in the supply of certain medical devices, where the medicinal products are inseparably connected with the devices, like it is the case with the diabetes pen or with vaccines prefilled in containers and syringes.

Strategy

Our team engaged in a multifaceted approach to safeguard the interests of the medicinal and medical devices. We provided strategic input during the consultation period with the European Chemicals Agency (ECHA), highlighting the unique needs and safety considerations of specific medical devices. This was followed by an extensive outreach to stakeholders within the European Parliament, the European Commission, and the EU member states. Our efforts focused on educating decision-makers about the indispensable role of PFAS in medicinal products and medical devices and the potential supply chain risks posed by a PFAS ban.

Results

Our advocacy efforts led to a pivotal development in the regulatory landscape on medical devices. Our targeted approach opened the door to potential derogations of several years for specific medical applications where there is substantial evidence that viable alternatives to PFAS do not exist. This ensures that essential medical devices remain available and effective, safeguarding patient care and industry stability.

Challenge

Alber & Geiger was retained by Terna, one of the leading construction companies in Greece, who was awarded the contract to construct and operate the Greek part of the 4,400km Central Motorway (E65) connecting Malmö in Sweden to Chania in Greece.

With only one section of the Greek part completed since the award of the tender, Terna relied on our support to get the approval for both the northern and southern sections of the motorway that had been pending for years under the European Commission’s State aid rules.

Strategy

Alber & Geiger targeted key officials in different Directorates of the European Commission to overcome the impasse on the State aid clearance. Alber & Geiger worked in tandem with Members of the European Parliament to gain support for the completion of the two remaining parts of the E65 motorway. We attached language that emphasised the strategic European dimension of that North-South axis through the EU, an EU project that actually had been planned for decades.

We also pointed out the contribution of the E65 motorway to competition and regional development. Moreover, we focused on the E65’s strategic importance for Greece, the South-East Europe region and the European transport road network, as well as its positive impact on jobs, tourism and investment.

Results

Our ability to combine legal, economic, social and political arguments ensured the approval of the entire project under the EU State aid rules. The European Commission cleared the funding for the construction of the southern part of the motorway. Later, the European Commission cleared the path for the construction of the northern section of the E65.

Challenge

Under the tobacco advertising directive, the EU Commission’s goal was to hunt down ‘insidious forms’ of tobacco advertising. For this reason, the directive had addressed both direct and indirect advertising to close loopholes. Davidoff and Lancaster had been accused of indirect tobacco advertising through the marketing of perfume products. The challenge was to convince the EU Commission in particular and the EU institutions in general that promoting the Davidoff brand image was not tobacco advertising.

Strategy

The strategy focused on the differentiation between direct and indirect tobacco advertising which the directive had established. The latter being mainly based on a brand diversification strategy of companies. In most cases these brand diversifications were meanwhile brand products of their own, not connected to tobacco products in any way.

But the directive’s wording not only addressed the marketing and advertising of such a diversification product like perfumes or clothes. It actually also addressed the diversification product itself, considering the sheer existence of the perfume as indirect tobacco advertising.

Results

We prevented the EU Commission from getting entangled into a wasteful litigation that would have compromised legitimate economic activity. Insofar as issues for Davidoff remained unresolved by lobbying we successfully executed a CJEU case.

Meet our Team

As the leading EU government relations law firm our team consistently ranks among the EU’s best.

Press

What others say about us

Meet us in the News